Literature DB >> 23732282

Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours.

Steven K Libutti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23732282     DOI： 10.1038/nrendo.2013.109

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.

Authors:  Allen M Spiegel; Steven K Libutti
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

2.  A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.

Authors:  Diane L Reidy-Lagunes; Efsevia Vakiani; Michal F Segal; Ellen M Hollywood; Laura H Tang; David B Solit; M Catherine Pietanza; Marinela Capanu; Leonard B Saltz
Journal:  Cancer       Date:  2012-03-21       Impact factor: 6.860

3.  Differential expression of alternatively spliced mRNA forms of the insulin-like growth factor 1 receptor in human neuroendocrine tumors.

Authors:  Lorenza Vitale; Luca Lenzi; Shane A Huntsman; Silvia Canaider; Flavia Frabetti; Raffaella Casadei; Federica Facchin; Paolo Carinci; Maria Zannotti; Domenico Coppola; Pierluigi Strippoli
Journal:  Oncol Rep       Date:  2006-05       Impact factor: 3.906

4.  The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.

Authors:  Michael Höpfner; Viola Baradari; Alexander Huether; Christof Schöfl; Hans Scherübl
Journal:  Endocr Relat Cancer       Date:  2006-03       Impact factor: 5.678

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

7.  Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1.

Authors:  H-C Jennifer Shen; Mei He; Anathea Powell; Asha Adem; Dominique Lorang; Charles Heller; Amelia C Grover; Kris Ylaya; Stephen M Hewitt; Stephen J Marx; Allen M Spiegel; Steven K Libutti
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

8.  Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

Authors:  Anthony W Tolcher; John Sarantopoulos; Amita Patnaik; Kyriakos Papadopoulos; Chia-Chi Lin; Jordi Rodon; Barbara Murphy; Bruce Roth; Ian McCaffery; Kevin S Gorski; Brianne Kaiser; Min Zhu; Hongjie Deng; Greg Friberg; Igor Puzanov
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

9.  Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.

Authors:  Thomas J Quinn; Ziqiang Yuan; Asha Adem; Rula Geha; Chakravarthy Vrikshajanani; Wade Koba; Eugene Fine; David T Hughes; Herbert A Schmid; Steven K Libutti
Journal:  Surgery       Date:  2012-10-24       Impact factor: 3.982

10.  A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.

Authors:  J R Strosberg; J A Chan; D P Ryan; J A Meyerhardt; C S Fuchs; T Abrams; E Regan; R Brady; J Weber; T Campos; L K Kvols; M H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678
  10 in total
  3 in total

Review 1.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Mark Kidd; Irvin Modlin; Kjell Öberg
Journal:  Nat Rev Clin Oncol       Date:  2016-06-07       Impact factor: 66.675

2.  Metformin use and young age lung cancer: A case series report.

Authors:  B O Deng; Y I Wang; Dong Xie; Shawn M Stoddard; Ping Yang
Journal:  Oncol Lett       Date:  2016-03-08       Impact factor: 2.967

3.  Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells.

Authors:  Kristina B V Døssing; Christina Kjær; Jonas Vikeså; Tina Binderup; Ulrich Knigge; Michael D Culler; Andreas Kjær; Birgitte Federspiel; Lennart Friis-Hansen
Journal:  Genes (Basel)       Date:  2018-07-04       Impact factor: 4.096
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.